TC011

TICAROS Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	TC011
Sponsor	TICAROS Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients (PHASE1, PHASE2)
Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TC011 CI brief — competitive landscape report
TC011 updates RSS · CI watch RSS
TICAROS Co., Ltd. portfolio CI